Glewis S, Michael M, Gurney H, Olver I, Zdenkowski N, Ackland S, Kukard C, Jayawardana M, Silva SSM, Alexander M, Tie J, Galettis P, Martin JH. Feasibility and population exposure of 5‐fluorouracil using therapeutic drug monitoring (PREDICT‐5FU): A multicentre clinical trial. British Journal of Clinical Pharmacology. 2025;91(7):10.1002/bcp.70006
Michael M, Wong R, Gill S, Strickland AH, Pavlakis N, Shapiro JD, Link E, Farrell M, Ngan SY, Tie J, Heriot AG, Goldstein D, Mitchell C, Roth S, Wilson K, Mui M, Ramsay RG, Segelov E. The Ave-Rec trial: Phase II trial of PDL1/PD-1 blockade with Avelumab post Chemoradiotherapy for locally advanced resectable T3B-4/N1-2 Rectal cancer.Clinical Cancer Research. 2025;:10.1158/1078-0432.ccr-25-0705
Zaman FY, Orchard SG, Polekhina G, Gibbs P, Bernstein WB, Macrae F, Tie J, Millar J, Gately L, Rodríguez LM, Van Londen G, Mar V, Hiscutt E, Adler N, Kent A, Ong WL, Haydon A, Warner E, Chan AT, Zalcberg J. Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adults. Journal of the National Cancer Institute. 2025;:10.1093/jnci/djaf145
Burge ME, Espinoza D, Sjoquist KM, Siu DH, Mercieca-Bebber R, Chantrill LA, Karapetis CS, Steer CB, Yip S, Cuff J, Winata S, Tie J, Thaker DA, Srivastav R, Abdi E, Strickland A, Segelov E, Francesconi A, Price T, Ladwa R, Joubert W, Tebbutt NC. AGITG MONARCC: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Trials Group (AGITG). Clinical Colorectal Cancer. 2025;24(2):10.1016/j.clcc.2024.11.003
Tie J, Wang Y, Loree JM, Cohen JD, Espinosa D, Wong R, Price TJ, Tebbutt NC, Lee M, Burge ME, Harris SJ, Lee B, Lynam JF, O’Callaghan CJ, Breadner DA, Bettegowda C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: Primary analysis of the ctDNA-positive cohort from the randomized AGITG dynamic-III trial (intergroup study of AGITG and CCTG).Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.3503
McLachlan S-A, Mostafa R, Sharpe L, Burge ME, Day F, Blum RH, Campbell R, Lynam JF, Lee B, Singh MS, Lee M, Chantrill LA, Lundy J, Wong ZW, Wong R, Joshi S, Saqib A, Karikios DJ, Gibbs P, Tie J. Circulating tumor DNA (ctDNA) analysis guiding adjuvant therapy in patients (pts) with colorectal cancer (CRC): Impact on fear of cancer recurrence (FCR).Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.11125
Chantrill LA, Samra JS, Tebbutt NC, Nikfarjam M, Reid D, Brungs D, Jaber M, Tie J, Mendis SR, Hong W, Cavicchiolo T, Cuff J, Hayes SJ, Christophersen LC, Roesner M, Maloney S. Neo-adjuvant chemo-immunotherapy in pancreatic cancer: Results of the Australasian Gastrointestinal Trials Group (AGITG) NEO-IMPACT pilot trial.Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.4189
Tie J, Melian M, Ruiz-Casado A, Wyrwicz L, Wysocki PJ, Stuebs P, Aranda E, Salas N, Elez E, Curigliano G, Radecka B, Parseghian C, Takacs I, Heinemann V, Vandal G, Huniti N, Vidal Barrul J. Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib (A), in combination with encorafenib (E) and cetuximab (C) in patients (pts) with previously treated BRAF V600E mutantmetastatic colorectal cancer (mCRC).Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.3551
Shi Q, Chang GJ, Pederson LD, Asare EA, Jin Z, Cohen R, Meyerhardt JA, Andre T, Tie J, Dixon JG, Palis BE, Ballman KV, Yothers G, Ma Z, Alberts SR, Shi C, Washington MK, Taieb J, Steele S, Goldberg RM. Proposed changes to the pathologic staging for colon cancer (CC): AJCC Colon Cancer Expert Panel (AJCCCCEP).Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.3520
Sanderson E, Gibbs P, Tie J. The emerging clinical utility of ctDNA to guide adjuvant treatment in cancer. The Lancet Regional Health – Western Pacific. 2025;59:10.1016/j.lanwpc.2025.101595
